Reported pain improvement following OVE for PVCS as measured by Visual Analogue Scale (VAS) | ||||||
---|---|---|---|---|---|---|
Reference | No of women | Mean age | Initial VAS | Follow-up VAS | Length of follow up (months) | Embolic agent |
Venbrux (2002) | 56 | 32.3 | 7.8 | 2.7 | 12 | Coils and sclerosant |
Chung (2003)Â | 52 | 40.1 | 7.8 | 3.2 | 26.6 | Coils |
Kim (2006) | 127 | 34 | 7.8 | 2.9 | 45 | Coils and sclerosant |
Laborda (2013)Â | 202 | 43.5 | 7.34 | 0.8 | 60 | Coils |
Hocquelet (2014)Â | 33 | 41.4 | 7.37 | 1.36 | 26 | Coils and sclerosant |
Lui (2019) | 12 | 36.5 | 6.7 | 2.7 | 24–36 | Coils and sclerosant |
De Gregori (2020) | 520 | 43.2 | 7.63 | 0.91 | 59 | Coils |
Nasser (2014)Â | 100 | 43.7 | 7.34 | 0.47 | 12 | Coils |
Senechal (2021)Â | 327 | 42 | 6.9 | 2 | 12 | Sclerosant |
Gandini (2008)Â | 38 | 36.9 | 7.8 | 4.2 | 12 | Coils |
Creton (2007)Â | 24 | 41.5 | 5 | 1.4 | 36 | Coils |
Tropeano (2008)Â | 22 | 36 | 8 | 3 | 12 | Sclerosant |
Asciutto (2009)Â | 35 | 49 | 5.2 | 1.2 | 36 | Coils |
Meneses (2013) | 10 | 38 | 8.2 | 1.36 | 24 | Sclerosant |
Mean(Range) | 111 (10–520) | 39 (32.3–49 | 7.2 (5–8.2) | 2.01 (0.47–4.2) | 28 (12–60) |  |